

REC Ref	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status
17/LO/0457	215990	The Bio-inspired Artificial Pancreas for the Home	Yes	20/07/2018	6			Yes	06/07/2017	16/04/2018			21/05/2018	
17/LO/1991	172966	A comparative study of two popular weight-loss diets and their effect on the metabolic profiles of: i) Healthy overweight and obese individuals ii) Overweight and obese breast cancer follow-up patients	Yes	30/01/2018	35			No	30/10/2017	18/12/2017	18/12/2017	30/10/2017	20/12/2017	
18/SW/0103	200303	A phase II prospective randomised clinical study of endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for inoperable ductal pancreatic carcinoma	No		2	41	43	No	26/03/2018	11/04/2018	31/05/2018	11/04/2018	01/06/2018	
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine	Yes	23/01/2018	51			No	20/02/2017	23/10/2017	06/04/2017	20/02/2017	23/01/2018	
17/LO/0566	218514	An experimental medicine study to validate The 18 kD Translocator Protein as a novel neuroimmunodulatory target	No		92	0	92	No	17/03/2017	11/01/2018	19/12/2017	17/03/2017	05/02/2018	
17/LO/1169	224716	Efficacy and usability of Ostom-i device in patients with ileostomy. A pilot study	No		25			No	25/09/2017	22/11/2017	20/10/2017	23/11/2017	23/11/2017	
17/LO/0939	219566	Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)	Yes	09/01/2018	1			No	12/09/2017	13/11/2017	08/11/2017	12/09/2017	18/12/2017	
17/LO/1095	225278	Investigation of the metabolic effects of duodenal resurfacing on insulin resistant women with polycystic ovarian syndrome	Yes	11/04/2018	35	22	57	No	09/06/2017	09/02/2018	04/09/2017	09/06/2017	20/03/2018	
17/SC/0554	225522	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study).	No		39	22	61	No	31/05/2017	10/10/2017	23/02/2018	21/03/2018	16/04/2018	
17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).	No		188			No	11/07/2017	01/11/2017	27/10/2017	02/03/2018	02/03/2018	
17/LO/1441	219916	SYNCope EDUcation for patients during tilt-table tests	Yes	20/03/2018	121			Yes	02/08/2017	17/01/2018	12/09/2017		12/02/2018	
17/LO/1457	227777	Randomised controlled trial of mechanochemical ablation versus cyanoacrylate adhesive for the treatment of varicose veins	Yes	06/11/2017	26	36	62	Yes	01/08/2017	23/10/2017	19/09/2017	30/10/2017	01/11/2017	
17/LO/1447	226100	The effectiveness of a focused point-of-care duplex ultrasound scan as a bedside screening tool to detect peripheral arterial disease in diabetes.	No		9	5	14	No	30/08/2017	06/11/2017	21/12/2017	15/12/2017	05/01/2018	
17/WS/0192	216416	Randomised controlled trial of foam sclerotherapy versus ambulatory phlebectomy for the treatment of varicose vein tributaries	Yes	22/01/2018	60			No	21/08/2017	15/10/2017	15/10/2017		22/11/2017	

17/LO/1040	226283	p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246	Yes	17/11/2017	38	61	99	No	19/07/2017	16/10/2017	04/09/2017	19/07/2017	17/10/2017	
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)	No		1	31	32	No	11/09/2017	13/10/2017	02/02/2018	15/08/2017	05/04/2018	
17/SC/0090	215068	A trial using ctDNA blood tests to detect cancer cells after standard treatment to trigger additional treatment in early stage triple negative breast cancer patients (c-TRAK-TN)	No		174			No	23/06/2017	31/07/2018	05/07/2017			
17/EE/0340	213113	INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy (BRAF+ MEKi) in patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma.	Yes	17/04/2018	82			No	01/08/2017	25/10/2017	15/10/2017	03/01/2018	15/01/2018	
17/EM/0338	229242	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Yes	12/09/2018	93			Within 70 Da	04/09/2017	07/02/2018	31/01/2018	04/05/2018	11/05/2018	
17/WS/0147	184216	Precision-Panc Master Protocol Personalising Treatment For Pancreatic Cancer	No		90			Within 70 Da	29/08/2017	24/11/2017	05/01/2018	24/11/2017	09/08/2018	
17/LO/1847	216867	A randomised phase II trial of Selinexor, cyclophosphamide and prednisone vs cyclophosphamide and prednisone in relapsed or refractory multiple myeloma (RRMM) patients.	Yes	20/07/2018	136			Within 70 Da	22/11/2017	14/02/2018	04/01/2018	11/03/2018	15/05/2018	
17/LO/1500	224823	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation Who are candidates for Non-intensive Therapy.	No		55	7	62	Within 70 Da	05/02/2018	13/02/2018	06/03/2018	10/09/2017	29/06/2018	
17/SC/0201	209172	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study.	Yes	23/05/2018				Within 70 Da	29/01/2018	22/03/2018	18/10/2017	07/05/2018	16/05/2018	
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy	Yes	29/05/2018	30	34	64	No	10/07/2017	26/03/2018	21/11/2017	19/04/2018	25/04/2018	
17/NE/0331	229957	A prospective, global, multicentre, real world outcome study of fenestrated endovascular aneurysm repair using the fenestrated Anaconda (TM) device	Yes	18/04/2018	55	63	118	Within 70 Da	05/06/2017	21/12/2017	20/12/2017	14/02/2018	14/02/2018	
18/LO/0217	235711	INvestigational Study Into Transplantation of the Uterus (INSITU)	No		32			Yes	24/01/2018	23/04/2018	28/02/2018	25/05/2018	25/05/2018	
17/LO/1695	234684	A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Medicated Gene Transfer of Human Factor VIII in Haemophilia A Patients with Residual FVIII Levels < 1 IU/dl Receiving Prophylactic FVIII Infusions.	Yes	01/04/2018	65			No	09/10/2017	09/10/2017	24/11/2017		13/12/2017	
16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.	No		40			No	12/10/2017	23/02/2018	05/12/2016	08/02/2018	04/04/2018	
17/LO/1918	229435	Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients with Intermittent Claudication (NESIC) compared to best available treatment? A Multicentre Randomised Controlled Study	Yes	08/03/2018	45	20	65	No	09/11/2017	02/01/2018	29/01/2018		16/02/2018	

17/NE/0151	223815	Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia (SGI-110-06).	No		135			Within 70 Da	01/11/2017	01/11/2017	19/07/2017	07/03/2018	16/03/2018	
17/LO/1929	233885	A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)	No		148			No	02/11/2017	13/11/2017	05/02/2018	27/03/2018	10/04/2018	Sponsor decl
17/EE/0481	226412	Pre-Implantation trial of Histopathology In renal Allografts	No		74			No	08/11/2017	24/11/2017	05/01/2018	08/11/2017	06/02/2018	
18/LO/0196	237129	A Study of Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion (CSII) in Adults with Type 1 Diabetes	Yes	10/04/2018	16			Within 70 Da	10/01/2018	27/02/2018			15/03/2018	
17/NE/0300	225917	A phase II, randomised, double-blind, placebo-controlled, parallel-group, multicentre study investigating the efficacy and safety of Sepranolone (UC1010) in patients with PMDD	Yes	04/07/2018	22	35	57	No	06/11/2017	08/05/2018	31/10/2017	30/05/2018	30/05/2018	
17/LO/0118	220143	Maternal Moments: Investigating music listening of well-being in pregnancy	Yes	07/08/2018	7			No	03/11/2017	14/12/2017	28/04/2017	14/12/2017	21/12/2017	
18/LO/1063	236384	The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study.	No		37	60	97	No	16/10/2017	28/08/2018	12/07/2018	29/08/2018	05/10/2018	
17/EE/0368	213669	STRESS-L: SStudy into the REversal of Septic Shock with Landiolol (Beta Blockade)	Yes	03/07/2018	114			Within 70 Da	12/10/2017	28/03/2018	10/11/2017	12/03/2018	04/05/2018	
17/EE/0498	239464	Pain relief with disease modification by Capsaicin 8% patch: a clinical study in Diabetic Peripheral Neuropathy	No		117			No	28/11/2017	12/03/2018	12/03/2018	04/07/2018	04/07/2018	
17/EE/0480	235288	A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)	No		103			No	27/11/2017	14/12/2017	05/02/2018	27/03/2018	10/04/2018	Sponsor decl
17/LO/2059	235808	A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)	No					No	27/11/2017	14/12/2017	29/01/2018	20/03/2018	27/03/2018	Sponsor decl
17/SC/0641	238111	A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels \geq 1 IU/dL and Pre-existing Antibodies Against AAV5	No		117			Yes	08/12/2017	08/12/2017				Sponsor decl
18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	No		14	26	40	Yes	22/10/2017	19/01/2018	11/04/2018		16/05/2018	
18/LO/0054	236047	Microneedle sensing of beta-lactam antibiotic concentrations in human interstitial fluid	Yes	30/04/2018	15			No	06/07/2017	21/03/2018	14/02/2018	06/07/2017	04/04/2018	
17/LO/0103	216784	A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache	No		11			No	20/06/2017	20/12/2017	05/07/2017		04/01/2018	

17/LO/0102	215259	A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/ Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of CHRONIC Cluster Headaches (CCH)	No		12			No	12/12/2016	22/12/2017	14/07/2017	12/12/2016	02/01/2018	
17/NE/0181	220972	Feasibility study for the use of intraoperative single dose radiotherapy for locally advanced and recurrent pelvic cancer	No		129	90	219	No	20/04/2017	05/10/2017	06/09/2017		17/10/2017	
16/SS/0137	199347	Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis 2	Yes	14/06/2018	55	76	131	No	24/04/2017	07/11/2017	11/01/2017	24/04/2017	16/03/2018	
17/WM/0425	232819	A phase III trial evaluating the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents with HDM allergic asthma	Yes	04/04/2018	37			Within 70 Da	27/04/2017	24/11/2017	15/01/2018	18/01/2018	18/01/2018	
17/LO/0525	221541	A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORTÃ,Â® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).	No		42	71	113	No	05/12/2016	25/10/2017	30/06/2017	30/11/2017	01/12/2017	
17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Yes	01/02/2018	43	11	54	No	18/04/2017	11/10/2017	02/08/2017	22/11/2017	22/11/2017	
17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)-STELLAR 4	Yes	04/12/2017	3			Site Not Con	31/08/2017	11/10/2017	02/08/2017		23/11/2017	
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimerâ€™s Disease	Yes	13/06/2018	4	115	119	No	23/05/2017	30/04/2018	21/08/2017	23/05/2017	03/05/2018	
17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinsonâ€™s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLEM)	Yes	02/02/2018	0			Within 70 Da	08/06/2017	06/10/2017	27/06/2017	08/06/2017	10/10/2017	
17/EM/0236	221138	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in Parkinson's Disease (PD).	No		32			Yes	19/06/2017	18/12/2017	08/08/2017	19/06/2017	18/12/2017	
18/LO/0091	140718	Side-Stream Dark Field video analysis of cerebral microcirculation in patients with traumatic brain injury or a brain tumour: the effects of blood pressure and intracranial pressure	No					Within 70 Da	12/12/2017	12/02/2018	12/02/2018		16/03/2018	
17/YH/0296	222979	Optimising the identification of acute deterioration and sepsis through wearable sensors and digital alerting.	No		159			Within 70 Da	04/08/2017	16/10/2017	27/09/2017			
17/LO/1660	223181	Feasibility of Improving Risk Stratification in Brugada Syndrome	Yes	05/10/2018	16	46	62	No	28/02/2018	10/08/2018	22/11/2017	05/10/2018	05/10/2018	
17/NW/0352	226135	Resuscitative Endovascular Balloon Occlusion of the Aorta for Trauma	No		0			Within 70 Da	03/07/2017	05/10/2017	10/08/2017	20/12/2017	13/03/2018	
17/EM/0301	209448	Sedation and Weaning in Children	Yes	05/02/2018	26	38	64	Within 70 Da	13/07/2017	05/12/2017	29/09/2017	20/12/2017	21/12/2017	
17/EE/0387	231908	Maraviroc Add-On Therapy for Steatohepatitis in HIV	Yes	19/06/2018				Within 70 Da	30/08/2017	01/05/2018	08/03/2018	01/05/2018	01/05/2018	

17/LO/1568	232931	Pharmacokinetics of Intramuscular Adrenaline in Food-Allergic Teenagers - does dose matter? The PIMAT study	Yes	16/12/2017	38			No	30/08/2017	13/10/2017	30/10/2017	08/11/2017	08/11/2017	
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	No		25	31	56	No	31/07/2017	14/05/2018	28/11/2017	31/07/2017	21/06/2018	
17/LO/1245	208149	A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis	Yes	08/03/2018	14			No	11/09/2017	11/01/2018	10/11/2017	11/09/2017	05/02/2018	
17/EM/0361	234065	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies (AFFINITY)	No					Within 70 Da	20/09/2017	28/02/2018	11/01/2018	20/09/2017	14/03/2018	
17/SC/0658	232220	SABRE- Serratus Anterior Block and catheter use in Rib fractures in the Emergency department	No					Within 70 Da	15/11/2017	12/06/2018	02/03/2018		18/07/2018	
17/LO/1693	233988	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levodopa in patients with Parkinson's Disease with motor fluctuations (iNDiGO)	No		133			Within 70 Da	04/10/2017	10/04/2018		04/10/2017		
16/LO/0831	196728	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment with Community-Acquired Pneumonia (CAP): a randomised controlled trial	Yes	28/09/2018	0			Within 70 Da	20/06/2017	26/10/2017	11/11/2016	08/03/2018	08/03/2018	
17/LO/0380	218003	PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	Yes	05/02/2018	156			Within 70 Da	25/01/2018	25/01/2018	18/05/2017	25/01/2018	25/01/2018	
17/SC/0582	234404	A multicentre, open-label, long-term safety study of AR101 characterised oral desensitisation immunotherapy in subjects who participated in a prior AR101 study	Yes	07/08/2018	39			Within 70 Da	24/10/2017	24/01/2018	18/01/2018	27/06/2018	29/06/2018	
16/LO/0680	186642	Strategy for maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17). A two-arm, phase 2/3 multicentre, open-label, randomised study evaluating safety and anti-viral effect of current anti-retroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants	No						08/11/2017	29/01/2018	28/07/2016	09/03/2018	09/03/2018	
18/EE/005	232671	A MULTICENTER, OPEN-LABEL STUDY TO ESTIMATE THE EFFECT SIZES OF HRCT ENDPOINTS IN RESPONSE TO GLUCOCORTICOID INDUCTION THERAPY IN SUBJECTS WITH PULMONARY SARCOIDOSIS	No		64	14	78		10/11/2017	19/07/2018				
17/LO/1478	226023	A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis	Yes	08/03/2018	23	67	90		22/09/2017	20/12/2017	23/11/2017	22/09/2017	22/02/2018	

17/EE/0474	229785	The open-label, randomised, multi-centre, parallel group, two-arm study to assess the safety, overall tolerability, and antiviral activity of Brincidofovir versus standard of care for treatment of adenovirus infections in high-risk paediatric allogeneic haematopoietic cell transplant recipients	Yes	10/04/2018	14				14/07/2017	10/01/2018	05/01/2018	02/02/2018	02/02/2018	
18/LO/0314	237195	Smart Catheter: A novel biosensor for early diagnosis of catheter associated urinary tract infection	No						21/02/2018	28/03/2018	06/04/2018		11/04/2018	
18/LO/0779	235161	A Randomized (1:1), Double blind, Multi center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF 0444913) or Azacitidine With or Without Glasdegib in Patients With Previously Untreated Acute Myeloid Leukemia.	No		31				18/12/2017	03/07/2018	15/06/2018			
18/LO/0700	238068	A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hSPCs) in Subjects with Transfusion-Dependent β^2 Thalassemia.	No		80				14/08/2018	18/05/2018	02/07/2018	13/09/2018	08/10/2018	
18/LO/0270	228830	Can NIRS be used as an intra-operative monitor of spinal cord function and predict patient outcome after vascular surgery?	No		24				06/04/2018	17/04/2018			18/05/2018	
17/SC/0639	236312	A Phase 3 Open-Label, single-Arm Study to Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Haemophilia A Patients with Residual FVIII Levels 1 IU/dL Receiving Prophylactic FVIII Infusions	No						09/01/2018	15/01/2018	26/02/2018	22/03/2018	05/04/2018	
18/LO/0070	238482	A Pivotal Clinical Trial of the Management of th Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System	Yes	20/09/2018	7				23/01/2018	30/04/2018	30/04/2018	10/05/2018	24/05/2018	
18/WS/0087	241031	Optimal duration of Cooling therapy in Mild Encephalopathy (COMET 1)	Yes	15/10/2018					02/05/2018	30/07/2018	18/06/2018	06/08/2018	06/08/2018	
18/YH/0212	237279	A phase Ib study of Itacitinib, a JAK1 inhibitor, in advanced hepatocellular carcinoma	No						14/08/2018	14/08/2018	14/08/2018	14/08/2018		
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebocontrolled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	No						15/01/2018	01/05/2018	04/12/2017		08/05/2018	
18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	No		27	8	35		11/04/2018	22/05/2018	15/05/2018	13/07/2018	19/07/2018	
18/LO/0170	236855	A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in combination with Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	No		39				29/01/2018	26/03/2018				
18/NW/0031	230387	A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine	No						12/02/2018	12/02/2018	08/02/2018			

18/LO/0376	236553	Investigating physiological effects of weight loss on male fertility	Yes	16/05/2018					23/03/2018	11/04/2018	11/04/2018		08/05/2018	
18/EM/0153	240773	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency	No						16/05/2018	31/08/2018	28/08/2018	24/09/2018	08/10/2018	
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	No						26/02/2018	04/06/2018	14/05/2018	13/07/2018	13/07/2018	
18/LO/0235	240315	An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials	No						28/02/2018	20/06/2018	17/04/2018			
18/LO/0512	196718	DICE Trial: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma)	No						05/03/2018	12/06/2018	05/06/2018		30/08/2018	
18/NW/0109	234734	PHIL evaluation in the endovascular treatment of intracranial dural AVF	No						26/02/2018	12/09/2018	14/05/2018	12/09/2018	12/10/2018	
18/SC/0057	230986	A prospective cross-sectional study analysing the utility of novel tablet-based audiometry and an interactive web-based hearing app as screening tools for drug-induced ototoxicity in adults with cystic fibrosis.	No						19/03/2018	19/03/2018	06/03/2018		20/04/2018	
18/LO/0393	240955	A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects with Severe Haemophilia B	No						15/03/2018	25/07/2018	20/06/2018	04/07/2018	14/09/2018	
16/LO/2150	201093	Randomised Phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum-resistant ovarian cancer	No						20/03/2018	20/03/2018	26/01/2017		17/08/2018	
18/SS/0010	238051	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	No						05/02/2018	04/05/2018	21/03/2018	01/08/2018	10/08/2018	
18/LO/0416	235395	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours	No						10/04/2018	30/07/2018	14/06/2018			
18/LO/0858	241447	A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY	No						13/04/2018	16/05/2018	12/07/2018			
18/LO/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	No						13/04/2018	05/06/2018	20/09/2018	09/03/2018		

18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	No						23/04/2018	21/06/2018	26/04/2018	07/08/2018	20/08/2018	
18/LO/0719	235423	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)	No						19/10/2017	10/07/2018		17/10/2018		
18/NE/0136	240494	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	No						02/05/2018	02/05/2018		13/02/2018		
18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Dose Finding, Placebo Controlled, Safety, Efficacy and Pharmacokinetic Study of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	No			49			21/09/2018	21/09/2018				
18/LO/1338	247728	PROSTAGRAM - Prostate Screening Trial using A Group of Radiological Approaches including MRI and ultrasound	No						10/07/2018	07/09/2018	10/09/2018	19/09/2018	19/09/2018	
18/YH/0097	241430	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)	No						29/05/2018	09/08/2018			10/08/2018	
18/LO/1187	240011	(A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy)	No						13/04/2018	25/07/2018		24/04/2018		
18/NS/0093	237699	Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation	No							26/09/2018			09/10/2018	
17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dyskinesia Study	No						14/06/2018	10/08/2018			10/08/2018	
17/EM/0406	235483	A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia (PRTX-100-202)	No						20/06/2018	20/06/2018	15/01/2018	16/08/2018	21/08/2018	
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	No						16/07/2018	31/07/2018				
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-Chek, Solo Micropump System vs. Multiple Daily Injection Therapy vs. mylife OmniPod in Patients with Type 1 Diabetes	No						12/06/2018	12/06/2018				
18/EM/0112	236871	A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission	No						20/06/2018	02/07/2018	12/06/2018	13/08/2018	16/08/2018	
17/SS/0105	209066	Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischaemic stroke with proven acute symptomatic occlusion	No						15/06/2018	27/09/2018				
18/LO/1289	245746	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.	No						19/07/2018	20/07/2018	05/09/2018		18/10/2018	
18/NE/0214	245998	MN39158 - A Long Term Extension Study in Multiple Sclerosis	No						26/07/2018	18/06/2018	11/07/2018		08/10/2018	

18/LO/1215	245798	A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 " Trial of erYaspase in pancreatic Cancer	No						06/07/2018	31/07/2018	22/08/2018	06/07/2018		
18/ES/0071		A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide	No						22/06/2018	28/09/2018				
18/LO/0330	236942	A pragmatic, multi-centre, three-armed randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment	No						31/07/2018	21/08/2018	25/05/2018	20/09/2018	20/09/2018	
18/EE/0260	230833	BN40031- CREAD Open Label Extension Study	No						18/09/2017	27/09/2018				
16/LO/0423	198451	A PHASE 1/2 TRIAL OF SRA737 (A CHK1 INHIBITOR) ADMINISTERED ORALLY IN SUBJECTS WITH ADVANCED CANCER	No						22/08/2018	22/08/2018				
18/WA/0276	246112	Randomised Double-Blind, Placebo-Controlled (within dose groups) and Active Controlled (Eplerenone group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients with Diabetic Nephropathy	No						03/09/2018	03/09/2018				
18/SC/0444	249450	A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response	No							07/09/2018	25/09/2018			
18/LO/1199	241759	Study to compare once-daily Extended Release tacrolimus Versus twice-daily Immediate Release Tacrolimus following renal allograft failure to Reduce the risk of Allosensitisation (EVITRA Trial)	No						07/08/2018	20/09/2018	13/08/2018	27/03/2018		
18/LO/1176	234823	PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODRONTAL TO MILD ALZHEIMER'S DISEASE	No						09/04/2018	11/07/2018	21/08/2018		19/09/2018	
17/EE/0382	220851	Predicting Outcomes From Crohn's Disease Using a Molecular Biomarker (PROFILE) Trial.	No						02/01/2018	15/06/2018		12/07/2018	25/07/2018	
18/SC/0055	239091	Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage	No						10/01/2018	11/09/2018	05/03/2018	28/09/2018	28/09/2018	
18/LO/0797	240879	A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients with Angle Closure Glaucoma.	No						18/01/2018	12/06/2018	02/10/2018			
18/LO/0012	225166	Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque, Injection 320 mgI/mL) on Renal Function in Adults with Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR).	No						15/02/2018	29/03/2018	08/03/2018			Sponsor decl
6/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial	No						14/03/2018	10/07/2018				

18/LO/0565	241439	Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)	No						12/04/2018	30/05/2018				
18/LO/0798	237827	DNAe Diagnostic Evaluation Study	No						04/06/2018	14/06/2018				03/09/2018
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	No						04/05/2018	16/07/2018				
17/SC/0244	226900	A randomised, parallel-group, double-blind, double-dummy, active controlled, multicentre study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids	No						09/05/2018	18/05/2018	27/07/2017	26/06/2018	06/07/2018	
18/LO/1070	174513	Improving the safety of oral immunotherapy for cow's milk allergy (The SOCMA Study)	Yes	15/08/2018					23/05/2018	18/07/2018	18/07/2018	19/07/2018	19/07/2018	
18/YH/0223	243476	Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care	No						07/06/2018	12/07/2018	09/07/2018			
18/WA/0161	238902	WISARD: DTG+RPV FDC in patients with HIV-1 and the K103N mutation	No							10/09/2018				
17/EM/0406	235483	A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia (PRTX-100-202)	No						20/06/2018	20/06/2018				
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-Chek? Solo Micropump System vs. Multiple Daily Injection Therapy vs. mylife OmniPod? in Patients with Type 1 Diabetes	No						12/06/2018	12/06/2018				
17/EE/0382	220851	Predicting Outcomes From Crohn's Disease Using a Molecular Biomarker (PROFILE) Trial.	No							15/06/2018				
18/LO/0565	241439	Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)	No						12/04/2018	30/05/2018				
18/LO/0798	237827	DNAe Diagnostic Evaluation Study	No						04/06/2018	14/06/2018				
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	No						04/05/2018	30/05/2018				
17/SC/0244	226900	A randomised, parallel-group, double-blind, double-dummy, active controlled, multicentre study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids	No			49			09/05/2018	18/05/2018	27/07/2017	26/06/2018	06/07/2018	
18/NE/0214	180601	MN39158 - A Long Term Extension Study in Multiple Sclerosis	No							18/06/2018				
	240879	A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients with Angle Closure Glaucoma.	No							12/06/2018				

Date Site Ready To Start	A - Permissions delayed/denied	B - Suspend by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
							Y				Neither
20/12/2017											
	Y						Y				Neither
				Y							Sponsor
							Y				Neither
23/11/2017							Y				Neither
18/12/2017											
21/03/2018											
12/06/2018				Y			Y	Y			Sponsor
02/03/2018	Y			Y			Y	Y			Sponsor
30/10/2017											
				Y	Y						Sponsor
					Y	Y	Y			Y	Neither

06/04/2018				Y			Y				Sponsor
ined site confirmation										Y	NHS Provid
	Y					Y				Y	Neither
18/06/2018											
21/12/2017							Y				Neither
14/06/2018							Y				Neither
				Y			Y				Sponsor
ined site confirmation				Y				Y			Both
ined site confirmation											
ined site confirmation											
				Y					Y		Sponsor
04/04/2018											
							Y				Neither

23/11/2017	Y											Neither
22/06/2018							Y					Neither
							Y					Neither
							Y					Neither
				Y								Sponsor
20/03/2018				Y		Y	Y					Sponsor
12/07/2018				Y			Y	Y				Sponsor
04/04/2018				Y			Y					Sponsor
				Y								Sponsor
22/02/2018				Y				Y				Sponsor

20/02/2018						Y	Y				Neither
				Y							Sponsor
				Y							Sponsor
				Y				Y			Sponsor
							Y				Neither
				Y			Y	Y			Sponsor
24/05/2018						Y	Y				Neither
							Y				Neither
08/05/2018							Y				Neither
26/09/2018				Y			Y				Sponsor
				Y							Sponsor
				Y							Sponsor

31/07/2018					Y			Y			Neither
				Y							Sponsor
04/09/2018				Y							Sponsor
							Y				Neither
12/09/2018				Y				Y			Sponsor
07/09/2018				Y			Y	Y			Sponsor
				Y							Sponsor
				Y							Sponsor

				Y			Y				Sponsor
				Y							Sponsor
				Y							Sponsor
14/08/2018											
16/08/2018											
				Y							Sponsor
	Y										Neither
17/09/2018				Y			Y				Sponsor
				Y							Sponsor
				Y							Sponsor

				Y							Sponsor
27/07/2018							Y				Neither
				Y							Sponsor
ined site confirmation			Y								Sponsor
				Y							Sponsor

